Sebastien Hotte

Sebastien Hotte

UNVERIFIED PROFILE

Are you Sebastien Hotte?   Register this Author

Register author
Sebastien Hotte

Sebastien Hotte

Publications by authors named "Sebastien Hotte"

Are you Sebastien Hotte?   Register this Author

91Publications

2140Reads

50Profile Views

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases.

Asian J Androl 2019 Sep 13. Epub 2019 Sep 13.

Department of Oncology, McMaster University, Hamilton, ON L8N 4A6, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/aja.aja_66_19DOI Listing
September 2019

Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.

Can Urol Assoc J 2019 Jul 23. Epub 2019 Jul 23.

Centre Hospitalier de l'Université de Montréal, Division of Oncology, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.5946DOI Listing
July 2019

Reversible Cabozantinib-Induced Cardiomyopathy.

Can J Cardiol 2019 04 29;35(4):544.e1-544.e2. Epub 2018 Dec 29.

The Division of Cardiology, Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cjca.2018.12.025DOI Listing
April 2019

Exogenous estrogen therapy, testicular cancer, and the male to female transgender population: a case report.

J Med Case Rep 2018 Dec 19;12(1):373. Epub 2018 Dec 19.

Department of Oncology, McMaster University, Juravinski Cancer Centre, 699 Concession St, Hamilton, ON, L8V 5C2, Canada.

View Article

Download full-text PDF

Source
https://jmedicalcasereports.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13256-018-1894-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299550PMC
December 2018

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2018 05 2;36(15):1521-1539. Epub 2018 Apr 2.

Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and Rick Bangs, patient representative.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.0619DOI Listing
May 2018

A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.

Invest New Drugs 2018 04 18;36(2):278-287. Epub 2017 Dec 18.

Division of Medical Oncology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0553-xDOI Listing
April 2018

Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Ann Intern Med 2017 Sep 8;167(5):341-350. Epub 2017 Aug 8.

From University of Toronto, University Health Network, Odette Cancer Centre, and Princess Margaret Hospital, Toronto; McMaster University and Juravinski Cancer Centre, Hamilton; University of Ottawa and The Ottawa Hospital Cancer Centre, Ottawa; and Western University and London Health Sciences Centre, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/M16-2577DOI Listing
September 2017

Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.

Future Oncol 2017 Feb 7;13(4):369-379. Epub 2016 Oct 7.

Department of Oncology, Division of Medical Oncology, Juravinski Cancer Centre, 699 Concession Street, Hamilton, Ontario, L8V 5C2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0279DOI Listing
February 2017

Localized prostate cancer.

Can Urol Assoc J 2016 Aug;10(7-8Suppl3):S138-S139

Associate Professor, Department of Oncology, Division of Medical Oncology, McMaster University; Medical Oncologist, Juravinski Cancer Centre, Hamilton, ON, Canada.

View Article

Download full-text PDF

Source
http://www.cuaj.ca/index.php/journal/article/view/4054
Publisher Site
http://dx.doi.org/10.5489/cuaj.4054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120981PMC
August 2016

Chemotherapy research for metastatic prostate cancer.

Can Urol Assoc J 2016 Aug;10(7-8Suppl3):S140-S143

Associate Professor, Department of Oncology, Division of Medical Oncology, McMaster University; Medical Oncologist, Juravinski Cancer Centre, Hamilton, ON, Canada.

View Article

Download full-text PDF

Source
http://www.cuaj.ca/index.php/journal/article/view/4055
Publisher Site
http://dx.doi.org/10.5489/cuaj.4055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120982PMC
August 2016

Radionuclides.

Can Urol Assoc J 2016 Aug;10(7-8Suppl3):S144-S145

Associate Professor, Department of Oncology, Division of Medical Oncology, McMaster University; Medical Oncologist, Juravinski Cancer Centre, Hamilton, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.4056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120983PMC
August 2016

Androgen receptor axis-targeted agents.

Can Urol Assoc J 2016 Aug;10(7-8Suppl3):S146-S148

Associate Professor, Department of Oncology, Division of Medical Oncology, McMaster University; Medical Oncologist, Juravinski Cancer Centre, Hamilton, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.4057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120984PMC
August 2016

Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancer.

Heliyon 2016 Jan 22;2(1):e00059. Epub 2016 Jan 22.

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.heliyon.2015.e00059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945896PMC
January 2016

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.

Invest New Drugs 2014 Dec 19;32(6):1226-35. Epub 2014 Jul 19.

Cross Cancer Centre, 11560 University Ave NW, Edmonton, Alberta, T6G 1Z2, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0139-9DOI Listing
December 2014

Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy.

Urol Oncol 2014 Oct 11;32(7):975-80. Epub 2014 Jul 11.

Division of Urology, McMaster University, Hamilton, Ontario, Canada; Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2014.03.025DOI Listing
October 2014

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

J Clin Oncol 2014 Oct 8;32(30):3436-48. Epub 2014 Sep 8.

Ethan Basch, Ronald C. Chen, and Stacie B. Dusetzina, University of North Carolina, Chapel Hill; Derek Raghavan, Carolinas Health Care/Levine Cancer Institute, Charlotte, NC; D. Andrew Loblaw, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Ted Wootton, Patient Representatives, Toronto; Sebastian Hotte and Cindy Walker-Dilks, McMaster University; Cindy Walker-Dilks, Cancer Care Ontario, Hamilton; Eric Winquist, London Health Sciences Centre, London, Ontario; Fred Saad, University of Montreal, Montreal, Quebec, Canada; Thomas K. Oliver and R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Michael Carducci, Johns Hopkins University, Baltimore, MD; James N. Frame, Charleston Area Medical Center Health Systems, Charleston, WV; Kristina Garrels, Private Practice, Fargo, ND; Michael W. Kattan, Cleveland Clinic, Cleveland, OH; Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, MA; James Williams, Pennsylvania Prostate Cancer Coalition, Camp Hill, PA; Charles L. Bennett, South Carolina College of Pharmacy, Columbia, SC; and Katherine S. Virgo, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.8404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876355PMC
October 2014

Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods.

Clin Biochem 2014 Jul 12;47(10-11):897-900. Epub 2014 Apr 12.

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada; Escarpment Cancer Research Institute, Hamilton, ON L8V 5C2, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2014.03.027DOI Listing
July 2014

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.

Invest New Drugs 2013 Oct 17;31(5):1182-91. Epub 2013 Jul 17.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, 610 University Avenue, 5-125, M5G 2M9, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-013-0001-5
Publisher Site
http://dx.doi.org/10.1007/s10637-013-0001-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771370PMC
October 2013

MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma.

Cancer Invest 2012 Jun;30(5):415-21

Department of Internal Medicine, The University of Texas Medical School/ Memorial Hermann Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/07357907.2012.675381DOI Listing
June 2012

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.

Invest New Drugs 2011 Oct 27;29(5):1045-9. Epub 2010 Feb 27.

Princess Margaret Hospital, Phase II Consortium, 610 University Avenue, Suite 5-222, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-010-9408-4
Publisher Site
http://dx.doi.org/10.1007/s10637-010-9408-4DOI Listing
October 2011

High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre.

Sarcoma 2004 ;8(2-3):63-9

Department of Medicine McMaster University and Division of Medical Oncology Hamilton Regional Cancer Centre (HRCC) 699 Concession Street Hamilton Ontario L8V 5C2 Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13577140410001710521DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395608PMC
July 2011

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.

Cancer Chemother Pharmacol 2011 Apr 3;67(4):927-33. Epub 2010 Jul 3.

Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, Toronto, ON M5G 2M9, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1389-7DOI Listing
April 2011

Guidelines for the management of castrate-resistant prostate cancer.

Can Urol Assoc J 2010 Dec;4(6):380-4

Director of Urologic Oncology Centre Hospitalier de l'Université de Montréal, Montréal, QC;

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997826PMC
http://dx.doi.org/10.5489/cuaj.10167DOI Listing
December 2010

Case report: Celiac disease masquerading as bone metastasis in a 29-year-old woman.

J Clin Oncol 2010 Nov 30;28(31):e623-5. Epub 2010 Aug 30.

McMaster University, Juravinski Cancer Center, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.29.6269DOI Listing
November 2010

The unclear zone in phase II clinical trials.

Eur J Cancer 2010 Sep 26;46(13):2408-13. Epub 2010 Jun 26.

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2010.05.027DOI Listing
September 2010

Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent.

Clin Biochem 2009 Jul 21;42(10-11):1162-5. Epub 2009 Apr 21.

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S000991200900188
Publisher Site
http://dx.doi.org/10.1016/j.clinbiochem.2009.04.008DOI Listing
July 2009

Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1.

Expert Opin Investig Drugs 2009 Mar;18(3):311-25

Juravinski Cancer Centre, Department of Oncology, Hamilton, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543780902752463DOI Listing
March 2009

Understanding the results of meta-analyses in the treatment of head and neck squamous cell cancer.

Hematol Oncol Clin North Am 2008 Dec;22(6):1257-66, x

Department of Oncology, McMaster University, 699 Concession Street, Hamilton, Ontario L8V 5C2, Canada.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S088985880800127
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2008.09.001DOI Listing
December 2008

Treatment of adult rhabdoid renal cell carcinoma with sorafenib.

Can Urol Assoc J 2008 Dec;2(6):631-4

Division of Urology, Department of Surgery, McMaster University, Hamilton, Ont., and the.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2593598PMC
http://dx.doi.org/10.5489/cuaj.983DOI Listing
December 2008

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.

Clin Cancer Res 2008 Jun;14(11):3450-5

Juravinski Cancer Centre at Hamilton Health Sciences, 699 Concession Street, Hamilton, Ontario, Canada L8V 5C2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1416DOI Listing
June 2008

Cardiotoxicity associated with sunitinib.

Lancet 2008 Apr;371(9620):1244; author reply 1245

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(08)60551-6DOI Listing
April 2008

Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).

Invest New Drugs 2007 Oct 28;25(5):471-7. Epub 2007 Mar 28.

Department of Medical Oncology, University Health Network-OCI/Princess Margaret Hospital, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-007-9044-9
Publisher Site
http://dx.doi.org/10.1007/s10637-007-9044-9DOI Listing
October 2007

Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma.

Biochim Biophys Acta 2007 Oct 12;1772(10):1134-42. Epub 2007 Jul 12.

Division of Nephrology, Department of Medicine, McMaster University, and Father Sean O'Sullivan Research Centre, St. Joseph's Hospital, 50 Charlton Ave East, Hamilton, ON, Canada L8N 4A6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbadis.2007.07.001DOI Listing
October 2007

Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma.

Can Urol Assoc J 2007 Jun;1(2 Suppl):S28-33

Department of Surgery (Urology), McMaster University.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2422946PMC
http://dx.doi.org/10.5489/cuaj.65DOI Listing
June 2007

Systemic therapy for patients with advanced, unresectable ormetastatic renal cell carcinoma: moving to guidelines.

Can Urol Assoc J 2007 Jun;1(2 Suppl):S34-40

Department of Oncology, Juravinski Cancer Centre.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2422947PMC
http://dx.doi.org/10.5489/cuaj.66DOI Listing
June 2007

An optimized clinical regimen for the oncolytic virus PV701.

Clin Cancer Res 2007 Feb;13(3):977-85

Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1817DOI Listing
February 2007

Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.

Curr Opin Mol Ther 2003 Dec;5(6):618-24

Wellstat Biologics Corporation, 930 Clopper Road, Gaithersburg, MD 20878, USA.

View Article

Download full-text PDF

Source
December 2003

BAY 43-9006: early clinical data in patients with advanced solid malignancies.

Curr Pharm Des 2002 ;8(25):2249-53

Department of Medicine, McMaster University and Division of Medical Oncology, Hamilton Regional Cancer Centre, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612023393053DOI Listing
March 2003

Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.

Cancer 2002 Aug;95(3):506-12

Department of Oncology, University of Western Ontario, London Regional Cancer Center, 790 Commmissioners Road East, London, Ontario, Canada N6A 4L6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.10709DOI Listing
August 2002